]>
IRCT20210211050323N3 IRCT 2022-02-24 Hamedan University of Medical Sciences The effect of rosuvastatin in multiple sclerosis Clinical trial to evaluate the effect of rosuvastatin as adjunctive therapy on cytochrome b-245 beta chain (CYBB) gene expression in patients with multiple sclerosis 2022-04-04 anticipated 40 Complete https://irct.ir/trial/61855 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Multiple sclerosis. Intervention group: Resvostatin, 20 mg tablets, once daily, for 3 months. No - There is not a plan to make this available Justification or reason for not sharing IPD is No additional information.
public Maryam Atminani Esfahani
Hamedan University of Medical Sciences , Shahid Fahmideh St. , Hamedan
Hamedan Iran (Islamic Republic of) 6517838687 +98 81 3252 0182 m.etminani@umsha.ac.ir Hamedan University of Medical Sciences scientific Maryam Atminani Esfahani
Hamedan University of Medical Sciences , Shahid Fahmideh St. , Hamedan
Hamedan Iran (Islamic Republic of) 6517838687 +98 81 3252 0182 m.etminani@umsha.ac.ir Hamedan University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) History of multiple sclerosis at least one year ago Radiographic findings of magnetic resonance imaging ( MRI ) consistent with the clinical diagnosis of multiple sclerosis No other concomitant inflammatory disease Bad cholesterol levels (low-density lipoprotein) less than 130 mg / dL No pregnancy and lactation The consistency of the main treatment of patients and the use of a specific type of drug Do not take medications other than standard treatments for multiple sclerosis that alter the levels of the factors under consideration. Do not use any combination with antioxidant effects in the past month. 20 years 70 years Both Existing evidence-based on increased patient disability Consumption of any combination, or drugs with antioxidant effects except prescription drugs The existence of any cognitive or behavioral disorders with an effect on the patient's cooperation G35 Multiple sclerosis Treatment - Drugs Intervention group: Resvostatin, 20 mg tablets, once daily, for 3 months Cytochrome b-245 beta chain (CYBB) gene expression. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Laboratory. Expanded Disability Status Scale (EDSS ) score. Timepoint: Before the intervention and 3 months after the start of the intervention. Method of measurement: Expanded Disability Status Scale (EDSS) questionnaire. Hamedan University of Medical Sciences Approved 2021-11-27 Ethics Committee of Hamedan University of Medical Sciences Hamedan University of Medical Sciences , Shahid Fahmideh St. , Hamedan Hamedan Hamadan Iran (Islamic Republic of)